Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

SIVA1 (SIVA1, Apoptosis-Inducing Factor)

Written2013-10João Agostinho Machado-Neto, Fabiola Traina
Hematology, Hemotherapy Center-University of Campinas/Hemocentro-Unicamp, Instituto Nacional de Ciencia e Tecnologia do Sangue, Campinas, Sao Paulo, Brazil (JAMN, FT); Hematology/Oncology Division, Department of Internal Medicine, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil (FT)

(Note : for Links provided by Atlas : click)

Identity

Alias_symbol (synonym)SIVA
Siva-1
Siva-2
CD27BP
Other alias
HGNC (Hugo) SIVA1
LocusID (NCBI) 10572
Atlas_Id 42301
Location 14q32.33  [Link to chromosome band 14q32]
Location_base_pair Starts at 104753133 and ends at 104759659 bp from pter ( according to hg19-Feb_2009)  [Mapping SIVA1.png]
Fusion genes
(updated 2016)
SIVA1 (14q32.33) / SQSTM1 (5q35.3)XRCC6 (22q13.2) / SIVA1 (14q32.33)

DNA/RNA

Description The entire SIVA1 gene is about 15.3 Kb and contains 4 exons (Start: 105219437 bp and End: 105234831; Orientation: plus strand). Two alternatively-spliced transcript variants encoding distinct proteins have been described, SIVA1 transcript variant 1, which is the predominant transcript variant with a cDNA containing 790 bp (codifying the SIVA1 protein), and the SIVA1 transcript variant 2 lacking the exon 2 with a cDNA containing 595 bp (codifying the SIVA2 protein).

Protein

Description SIVA1 contains a unique amphipathic helical region (SAH) in the N-terminal region, a death domain homology region (DDHR) in the central part of the protein, and a Zinc finger-like structure at its C-terminal region. The SIVA2 isoform lacks the DDHR domain (Figure 1).
 
  Figure 1. Schematic structure of SIVA1 and SIVA2 proteins. The amphipathic helical region (SAH) at the N-terminal region, a death domain homology region (DDHR) in the central section, and a Zinc finger-like (ZF) structure at its C-terminal region are illustrated. The amino acids (aa) positions are indicated.
Expression Ubiquitous.
Localisation SIVA1 is found in the nucleus and cytoplasm (Figure 2).
 
  Figure 2. Intracellular localization of SIVA1 protein in a prostate cancer cell line. Confocal analysis of LNCaP cells displaying SIVA (green), DAPI (blue) and Actin (red) staining; MERGE shows the overlapped images. Scale bar, 10 µm. Note the cytoplasmatic and nuclear localization of SIVA1. Anti-SIVA1 (sc-7436) was from Santa Cruz Biotechnology, (Santa Cruz, CA, USA), Phalloidin (A12379) and DAPI (P-36931) were from Invitrogen (Carlsbad, CA, USA). Personal data.
Function The proapoptotic function of SIVA1 is well elucidated and characterized. SIVA1 binds to death receptors, including CD27 and TNFRSF18, and plays a role in the transduction of the proapoptotic signal by the extrinsic pathway (Prasad et al., 1997; Spinicelli et al., 2002). SIVA1 interacts with BCL2 and BCL-XL, abrogates their antiapoptotic functions and modulates the intrinsic apoptosis pathway (Chu et al., 2004; Chu et al., 2005). In addition, SIVA1 associates with XIAP and regulates the apoptosis mediated by NFkB and JNK signaling (Resch et al., 2009). The SIVA gene is a transcription target of p53, p73 and E2F1 and is upregulated under stress or following DNA damage (Ray et al., 2011; Fortin et al., 2004).
Recently, novel partners and functions have been attributed to SIVA1. SIVA1 binds to and regulates p53 stability by acting as an adapter protein between p53 and MDM2, and participates in an auto-regulatory feedback loop between p53 and SIVA1 (Du et al., 2009; Mei and Wu, 2012). SIVA1 associates with ARF, enabling its ubiquitination and degradation; this mechanisms also regulates the p53/MDM2 signaling pathway (Wang et al., 2013).
Finally, SIVA1 is a novel adaptor protein that promotes Stathmin 1/CaMKII interaction. SIVA1 inhibits Stathmin 1 activity through Stathmin 1 phosphorylation at serine 16, which results in reduced cell migration and metastasis by stabilizing microtubules of tumor cells (Li et al., 2011). The main functions and signaling pathways of SIVA1 are illustrated in Figure 3.

The binding partners of SIVA1 are:
CD27: SIVA1 was initially identified by two-hybrid (Y2H) screening using CD27 as a bait, and its interaction was confirmed by immunoprecipitation (IP) of 293 cells co-expressing both proteins (Prasad et al., 1997). In agreement, Yoon et al. found that murine Siva1 and Siva2 also bind to CD27 (Yoon et al., 1999).
c-abl oncogene 2, non-receptor tyrosine kinase (ABL2): Y2H screening using ABL2 (previously known as ARG) as the bait identified SIVA1 as a binding partner. This protein association was confirmed by IP of MCF7 cells co-expressing FLAG-ABL2 and GFP-SIVA1 (Cao et al., 2001).
Tumor necrosis factor receptor superfamily, member 18 (TNFRSF18): TNFRSF18 (previously known as GITR) presents high homology with CD27. The interaction between TNFRSF18 and SIVA1 was identified using GST pull down and IP assays (Spinicelli et al., 2002).
BCL2-like 1 (BCL-XL): The association of BCL-XL and SIVA1 was first identified using purified GST-SIVA and BCL-XL proteins and confirmed by GST pull down assays using GST-SIVA1 in 293 cells expressing the GFP-BCL-XL protein (Xue et al., 2002). Later on, Chu et al. reported that the SAH region of SIVA1 was sufficient to specifically interact with BCL-XL (Chu et al., 2004).
B-cell CLL/lymphoma 2 (BCL2): The association of BCL2 and SIVA1 was verified using GST pull down assays with GST-SIVA in Cos-7 cells overexpressing full-length BCL2 protein, and this interaction occurred at the SAH region of SIVA1 (Chu et al., 2004).
CD4: Y2H screen using cytoplasmic domain of CD4 as the bait identified SIVA1. This protein interaction was confirmed by in vitro binding assays with GST-SIVA1. The interaction was mapped through GST pull-down assay using GST tagged deletion mutants of SIVA1; the C-terminal region of SIVA1 binds to the cytoplasmic domain of CD4 (Py et al., 2007).
Lysophosphatidic acid receptor 2 (LPAR2): Y2H screening using the C-terminal region of LPAR2 as the bait identified SIVA1. GST pull-down assays confirmed this protein association and the SIVA1 C-terminal region (aa 139-175) is required for this interaction (Lin et al., 2007).
Pyrin (MEFV): Y2H screening using Pyrin as the bait identified SIVA1 binding, and this association was confirmed by IP. Using deletion mutants of Pyrin and of SIVA1 or SIVA2, the C-terminal, rfp and SRPY domain of pyrin were found to interact with the N-terminal region of SIVA (Balci-Peynircioglu et al., 2008).
X-linked inhibitor of apoptosis (XIAP): Y2H screening using XIAP as the bait identified SIVA1 binding, and this protein association was confirmed by IP of 293 cells co-expressing both proteins (Resch et al., 2009).
FHL1 four and a half LIM domains 1 (FHL1): Y2H screening using the SLIMMER isoform of FHL1 as the bait identified SIVA; and this protein association was confirmed by IP. Three different isoforms of FHL1 were used in a Y2H assay for protein interaction mapping, SIVA1 binds only with the SLIMMER and not with FHL1 and KyoT2 isoforms (Cottle et al., 2009).
p53: The interaction between p53 and SIVA1 was tested by IP using H1229 cells co-expressing FLAG-p53 and GFP-SIVA1 and confirmed by IP using endogenous proteins from A549 cells. GST pull-down assays indicate that SIVA1 binds to p53 using its N-terminal region and DDHR, while p53 binds to SIVA1 via its DBD domain (Du et al., 2009).
Tyrosine kinase 2 (TYK2): Y2H screening using TYK2 as the bait identified SIVA1 binding, and this association was confirmed by IP of 293 cells co-expressing FLAG-SIVA1 and full-length TYK2. The SIVA1 N-terminal region binds to TYK2, as demonstrated by IP of 293T cells overexpressing GFP tagged deletion mutants of SIVA1 and FLAG-TYK2 (Shimoda et al., 2010).
Stathmin 1: Y2H screening using SIVA1 as bait identified Stathmin 1, and this association was confirmed by IP of U2OS cells co-expressing exogenous or endogenous SIVA1 and Stathmin 1 proteins (Li et al., 2011).
Cyclin-dependent kinase inhibitor 2A (CDKN2A), also known as ARF: The ARF and SIVA interaction was tested by IP assays of H1229 cells containing FLAG-SIVA1 and GFP-ARF, and purified recombinant proteins were used for confirmation. The protein interaction mapping was performed by GST pull down assays using deletion mutants of SIVA1 and ARF overexpressed in 293 cells. SIVA1 binds to ARF by its N-terminal region and DDHR, while the residue aa 21-64 of ARF is required (Wang et al., 2013).

 
  Figure 3. SIVA1 signaling pathway. (1) SIVA1 binds to death receptors and modulates the extrinsic apoptosis pathway. (2) SIVA 1 binds to BCL2 proteins family, inhibits the antiapoptotic proteins, BCL2 and BCL-XL, and leads to proapoptotic BAD protein oligomerization, and modulates the intrinsic apoptosis pathway. (3) SIVA1 binds to the XIAP protein and balances the proapoptotic and antiapoptotic signaling through the JNK and NFkB pathway, respectively, and modulates the extrinsic apoptosis pathway. (4) SIVA1 promotes Stathmin 1/CaMKII interaction, Stathmin 1 phosphorylation and inhibition, and modulates microtubule dynamics. (5) The SIVA1 gene is a transcription target of p53, p73 and E2F1. (6) SIVA1 protein acts as an adapter protein between p53 and MDM2, and promotes p53 ubiquitination. (7) SIVA1 acts as an ARF E3 ubiquitin ligase and regulates cell proliferation by the ARF/p53/MDM2 pathway. Abbreviations: P, phosphorylation; Ac, acetylation; Ub, ubiquitination. Figure was produced using Servier Medical Art.
Homology SIVA1 shares high homology (around 40%) in its DDHR domain with the FADD and RIP proteins. SIVA1 also shares a high homology with different species (Table 1).
 

Mutations

Note Mutations in the SIVA1 gene are rare, only six missense and one nonsense mutations are reported at COSMIC (Catalogue of somatic mutations in cancer).

Implicated in

Note
  
Entity Breast cancer
Note In breast cancer cells, SIVA1 acts synergistically with cisplatin in inducing apoptosis (Chu et al., 2005). Recently, SIVA1 protein has been reported to be downregulated in primary and metastatic breast cancer tumors and SIVA 1 negatively correlates with Stathmin 1 activity (Li et al., 2011). SIVA1 silencing augments metastasis in a xenograft breast cancer model (Li et al., 2011).
  
  
Entity Acute lymphoid leukemia
Note In acute lymphoid leukemia cell lines, SIVA1 overexpression induces apoptosis (Py et al., 2004), while SIVA1 inhibition reduces apoptosis (Resch et al., 2009).
  
  
Entity Colorectal cancer
Note In colorectal cancer samples, using a DNA array approach, SIVA1 has been shown to be downregulated when compared to normal tissue (Okuno et al., 2001). In colon cancer cell lines, SIVA1 was found to be a transcriptional target of p53 and E2F1 and to participate in the apoptosis induced by MDM2 inhibition (Ray et al., 2011). In addition, SIVA1 silencing reduces apoptosis in a p53-dependent manner in colon cancer cells treated with cisplatin (Barkinge et al., 2009).
  
  
Entity Osteosarcoma
Note In a xenograft osteosarcoma model, SIVA1 silencing increases p53 stability and augments the tumor growth (Du et al., 2009). In osteosarcoma cell lines, SIVA1 silencing increases cell migration and metastasis, while SIVA1 overexpression has an opposite effect (Li et al., 2011).
  
  
Entity Prostate cancer
Note In a study focused on the identification of genes modulated in prostate cancer cells under apoptosis, SIVA1 transcripts were found to be upregulated. This finding indicates a possible role of SIVA1 in the apoptotic pathway of prostate cancer cells (Lin and Ying, 1999).
  

To be noted

SIVA1 was initially identified as a potent protein in the induction of apoptosis, which led it to be given a similar name to the Hindu god of destruction, Shiva (Prasad et al., 1997). In 2009, the paradigm that SIVA1 has a function strictly related to apoptosis was broken when its role in p53 stability was reported. More recently, among the new roles proposed for SIVA1 are cell proliferation, migration and metastasis (Du et al., 2009; Mei and Wu, 2012).

Bibliography

Pyrin, product of the MEFV locus, interacts with the proapoptotic protein, Siva.
Balci-Peynircioglu B, Waite AL, Hu C, Richards N, Staubach-Grosse A, Yilmaz E, Gumucio DL.
J Cell Physiol. 2008 Sep;216(3):595-602. doi: 10.1002/jcp.21435.
PMID 18330885
 
The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis.
Barkinge JL, Gudi R, Sarah H, Chu F, Borthakur A, Prabhakar BS, Prasad KV.
J Carcinog. 2009;8:2.
PMID 19240372
 
The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress.
Cao C, Ren X, Kharbanda S, Koleske AJ, Prasad KV, Kufe D.
J Biol Chem. 2001 Apr 13;276(15):11465-8. Epub 2001 Feb 23.
PMID 11278261
 
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV.
Cancer Res. 2005 Jun 15;65(12):5301-9.
PMID 15958577
 
The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis.
Chu F, Borthakur A, Sun X, Barkinge J, Gudi R, Hawkins S, Prasad KV.
Apoptosis. 2004 Jan;9(1):83-95.
PMID 14739602
 
SLIMMER (FHL1B/KyoT3) interacts with the proapoptotic protein Siva-1 (CD27BP) and delays skeletal myoblast apoptosis.
Cottle DL, McGrath MJ, Wilding BR, Cowling BS, Kane JM, D'Arcy CE, Holdsworth M, Hatzinisiriou I, Prescott M, Brown S, Mitchell CA.
J Biol Chem. 2009 Sep 25;284(39):26964-77. doi: 10.1074/jbc.M109.036293. Epub 2009 Jul 29.
PMID 19643733
 
Suppression of p53 activity by Siva1.
Du W, Jiang P, Li N, Mei Y, Wang X, Wen L, Yang X, Wu M.
Cell Death Differ. 2009 Nov;16(11):1493-504. doi: 10.1038/cdd.2009.89. Epub 2009 Jul 10.
PMID 19590512
 
The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1.
Fortin A, MacLaurin JG, Arbour N, Cregan SP, Kushwaha N, Callaghan SM, Park DS, Albert PR, Slack RS.
J Biol Chem. 2004 Jul 2;279(27):28706-14. Epub 2004 Apr 22.
PMID 15105421
 
Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules.
Li N, Jiang P, Du W, Wu Z, Li C, Qiao M, Yang X, Wu M.
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12851-6. doi: 10.1073/pnas.1017372108. Epub 2011 Jul 18.
PMID 21768358
 
The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival.
Lin FT, Lai YJ, Makarova N, Tigyi G, Lin WC.
J Biol Chem. 2007 Dec 28;282(52):37759-69. Epub 2007 Oct 26.
PMID 17965021
 
Differentially expressed genes in activin-induced apoptotic LNCaP cells.
Lin S, Ying SY.
Biochem Biophys Res Commun. 1999 Apr 2;257(1):187-92.
PMID 10092531
 
Multifaceted functions of Siva-1: more than an Indian God of Destruction.
Mei Y, Wu M.
Protein Cell. 2012 Feb;3(2):117-22. doi: 10.1007/s13238-012-2018-5. Epub 2012 Mar 17. (REVIEW)
PMID 22426980
 
Gene expression analysis in colorectal cancer using practical DNA array filter.
Okuno K, Yasutomi M, Nishimura N, Arakawa T, Shiomi M, Hida J, Ueda K, Minami K.
Dis Colon Rectum. 2001 Feb;44(2):295-9.
PMID 11227951
 
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.
Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, Schlossman SF.
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6346-51.
PMID 9177220
 
The Siva protein is a novel intracellular ligand of the CD4 receptor that promotes HIV-1 envelope-induced apoptosis in T-lymphoid cells.
Py B, Bouchet J, Jacquot G, Sol-Foulon N, Basmaciogullari S, Schwartz O, Biard-Piechaczyk M, Benichou S.
Apoptosis. 2007 Oct;12(10):1879-92.
PMID 17653867
 
Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway.
Py B, Slomianny C, Auberger P, Petit PX, Benichou S.
J Immunol. 2004 Apr 1;172(7):4008-17.
PMID 15034012
 
Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM, Bhattacharya S, Johnson LR.
Apoptosis. 2011 Jan;16(1):35-44. doi: 10.1007/s10495-010-0538-0.
PMID 20812030
 
Siva1 is a XIAP-interacting protein that balances NFkappaB and JNK signalling to promote apoptosis.
Resch U, Schichl YM, Winsauer G, Gudi R, Prasad K, de Martin R.
J Cell Sci. 2009 Aug 1;122(Pt 15):2651-61. doi: 10.1242/jcs.049940. Epub 2009 Jul 7.
PMID 19584092
 
Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions.
Shimoda HK, Shide K, Kameda T, Matsunaga T, Shimoda K.
Biochem Biophys Res Commun. 2010 Sep 17;400(2):252-7. doi: 10.1016/j.bbrc.2010.08.051. Epub 2010 Aug 19.
PMID 20727854
 
GITR interacts with the pro-apoptotic protein Siva and induces apoptosis.
Spinicelli S, Nocentini G, Ronchetti S, Krausz LT, Bianchini R, Riccardi C.
Cell Death Differ. 2002 Dec;9(12):1382-4.
PMID 12478477
 
Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase.
Wang X, Zha M, Zhao X, Jiang P, Du W, Tam AY, Mei Y, Wu M.
Nat Commun. 2013;4:1551. doi: 10.1038/ncomms2533.
PMID 23462994
 
Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis.
Xue L, Chu F, Cheng Y, Sun X, Borthakur A, Ramarao M, Pandey P, Wu M, Schlossman SF, Prasad KV.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6925-30.
PMID 12011449
 
Murine Siva-1 and Siva-2, alternate splice forms of the mouse Siva gene, both bind to CD27 but differentially transduce apoptosis.
Yoon Y, Ao Z, Cheng Y, Schlossman SF, Prasad KV.
Oncogene. 1999 Nov 25;18(50):7174-9.
PMID 10597319
 

Citation

This paper should be referenced as such :
Machado-Neto, JA ; Traina, F
SIVA1 (SIVA1, Apoptosis-Inducing Factor)
Atlas Genet Cytogenet Oncol Haematol. 2014;18(5):334-339.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/SIVA1ID42301ch14q32.html


External links

Nomenclature
HGNC (Hugo)SIVA1   17712
Cards
AtlasSIVA1ID42301ch14q32
Entrez_Gene (NCBI)SIVA1  10572  SIVA1 apoptosis inducing factor
AliasesCD27BP; SIVA; Siva-1; Siva-2
GeneCards (Weizmann)SIVA1
Ensembl hg19 (Hinxton)ENSG00000184990 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000184990 [Gene_View]  chr14:104753133-104759659 [Contig_View]  SIVA1 [Vega]
ICGC DataPortalENSG00000184990
TCGA cBioPortalSIVA1
AceView (NCBI)SIVA1
Genatlas (Paris)SIVA1
WikiGenes10572
SOURCE (Princeton)SIVA1
Genetics Home Reference (NIH)SIVA1
Genomic and cartography
GoldenPath hg38 (UCSC)SIVA1  -     chr14:104753133-104759659 +  14q32.33   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)SIVA1  -     14q32.33   [Description]    (hg19-Feb_2009)
EnsemblSIVA1 - 14q32.33 [CytoView hg19]  SIVA1 - 14q32.33 [CytoView hg38]
Mapping of homologs : NCBISIVA1 [Mapview hg19]  SIVA1 [Mapview hg38]
OMIM605567   
Gene and transcription
Genbank (Entrez)AF033111 AF401214 AK124078 AK128704 AK223332
RefSeq transcript (Entrez)NM_006427 NM_021709
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)SIVA1
Cluster EST : UnigeneHs.112058 [ NCBI ]
CGAP (NCI)Hs.112058
Alternative Splicing GalleryENSG00000184990
Gene ExpressionSIVA1 [ NCBI-GEO ]   SIVA1 [ EBI - ARRAY_EXPRESS ]   SIVA1 [ SEEK ]   SIVA1 [ MEM ]
Gene Expression Viewer (FireBrowse)SIVA1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10572
GTEX Portal (Tissue expression)SIVA1
Protein : pattern, domain, 3D structure
UniProt/SwissProtO15304   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO15304  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO15304
Splice isoforms : SwissVarO15304
PhosPhoSitePlusO15304
Domains : Interpro (EBI)Siva_cd27-bd   
Domain families : Pfam (Sanger)Siva (PF05458)   
Domain families : Pfam (NCBI)pfam05458   
Conserved Domain (NCBI)SIVA1
DMDM Disease mutations10572
Blocks (Seattle)SIVA1
SuperfamilyO15304
Human Protein AtlasENSG00000184990
Peptide AtlasO15304
HPRD16124
IPIIPI00293157   IPI01010962   IPI01024933   IPI01025056   IPI00747156   
Protein Interaction databases
DIP (DOE-UCLA)O15304
IntAct (EBI)O15304
FunCoupENSG00000184990
BioGRIDSIVA1
STRING (EMBL)SIVA1
ZODIACSIVA1
Ontologies - Pathways
QuickGOO15304
Ontology : AmiGOvirus receptor activity  tumor necrosis factor receptor binding  CD27 receptor binding  protein binding  nucleoplasm  cytoplasm  viral entry into host cell  metal ion binding  extrinsic apoptotic signaling pathway  
Ontology : EGO-EBIvirus receptor activity  tumor necrosis factor receptor binding  CD27 receptor binding  protein binding  nucleoplasm  cytoplasm  viral entry into host cell  metal ion binding  extrinsic apoptotic signaling pathway  
NDEx NetworkSIVA1
Atlas of Cancer Signalling NetworkSIVA1
Wikipedia pathwaysSIVA1
Orthology - Evolution
OrthoDB10572
GeneTree (enSembl)ENSG00000184990
Phylogenetic Trees/Animal Genes : TreeFamSIVA1
HOVERGENO15304
HOGENOMO15304
Homologs : HomoloGeneSIVA1
Homology/Alignments : Family Browser (UCSC)SIVA1
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerSIVA1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)SIVA1
dbVarSIVA1
ClinVarSIVA1
1000_GenomesSIVA1 
Exome Variant ServerSIVA1
ExAC (Exome Aggregation Consortium)SIVA1 (select the gene name)
Genetic variants : HAPMAP10572
Genomic Variants (DGV)SIVA1 [DGVbeta]
DECIPHERSIVA1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisSIVA1 
Mutations
ICGC Data PortalSIVA1 
TCGA Data PortalSIVA1 
Broad Tumor PortalSIVA1
OASIS PortalSIVA1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICSIVA1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDSIVA1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch SIVA1
DgiDB (Drug Gene Interaction Database)SIVA1
DoCM (Curated mutations)SIVA1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)SIVA1 (select a term)
intoGenSIVA1
NCG5 (London)SIVA1
Cancer3DSIVA1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM605567   
Orphanet
MedgenSIVA1
Genetic Testing Registry SIVA1
NextProtO15304 [Medical]
TSGene10572
GENETestsSIVA1
Target ValidationSIVA1
Huge Navigator SIVA1 [HugePedia]
snp3D : Map Gene to Disease10572
BioCentury BCIQSIVA1
ClinGenSIVA1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10572
Chemical/Pharm GKB GenePA162403351
Clinical trialSIVA1
Miscellaneous
canSAR (ICR)SIVA1 (select the gene name)
Probes
Litterature
PubMed46 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineSIVA1
EVEXSIVA1
GoPubMedSIVA1
iHOPSIVA1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon May 22 09:23:22 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.